Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.27 AUD | +5.30% | +5.87% | -14.78% |
09/05 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
24/04 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.78% | 1.71B | |
+31.06% | 688B | |
+30.35% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.53% | 239B | |
+10.16% | 210B | |
-8.14% | 200B | |
+8.12% | 167B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023